Clinical trials: Nausea and Vomiting, Chemotherapy-Induced
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
- Trial name
- NCT00343460
- Testing
- APF530, dexamethasone, Palonosetron Hydrochloride
- Where
- 52 sites in United States
- Volunteers
- 1,428 people
- Sponsor
- Heron Therapeutics
Chemotherapy-Induced Nausea and Vomiting
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
The primary objective is to evaluate the efficacy of two different doses of IV palonosetron in the prevention of chemotherapy induced nausea and vomiting in MEC and HEC patients through 120 hours after start of chemotherapy in…
- Trial name
- NCT01442376
- Testing
- Palonosetron, Ondansetron
- Where
- 67 sites in United States, Argentina and 14 more
- Volunteers
- 502 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting
Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study
Olanzapine is licensed for use in adults in Canada and in teens in the US with mental illness. It is also often used for the management of mental illness in children.
- Trial name
- NCT02129478
- Testing
- Olanzapine
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- The Hospital for Sick Children
Chemotherapy-induced Nausea and Vomiting
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
In this study, patients will receive ondansetron 8mg and dexamethasone 10mg intravenously 30 minutes prior to myeloablative preparative chemotherapy until the last day of chemotherapy.
- Trial name
- NCT01370408
- Testing
- Palonosetron, ondansetron, Dexamethasone
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Northside Hospital, Inc.
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
RATIONALE: Gabapentin may prevent or reduce delayed nausea and vomiting caused by chemotherapy. It is not yet known whether gabapentin is more effective than a placebo in preventing nausea and vomiting.
- Trial name
- NCT00880191
- Testing
- dexamethasone, gabapentin
- Where
- 247 sites in United States
- Volunteers
- 430 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chemotherapy-Induced Nausea and Vomiting
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
- Trial name
- NCT00945321
- Testing
- aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
This study is designed to assess the safety and efficacy of palonesetron in preventing chemotherapy-induced nausea and vomiting (CINV) when administered to participants who have experienced either vomiting and or at least…
- Trial name
- NCT01054456
- Testing
- palonesetron
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Eisai Inc.
Chemotherapy-induced Nausea and Vomiting
Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting
The purpose of this research is to compare two drugs that are routinely used as standard of care for treating nausea and vomiting caused by chemotherapy.
- Trial name
- NCT05590923
- Testing
- OLA group: Olanzapine, DEX group: Dexamethasone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The Guthrie Clinic
Chemotherapy-induced Nausea and Vomiting
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
The purpose of the study is to mainly evaluate the efficacy and safety of aprepitant in combination with olanzapine ,palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients…
- Trial name
- AOPDPCINV (NCT02484911)
- Testing
- Olanzapine, Aprepitant, Palonosetron
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Chemotherapy-induced Nausea and Vomiting
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
The purpose of this study is to investigate the effectiveness of intravenous fosaprepitant therapy to reduce nausea and vomiting during the treatment of high dose interleukin-2 (HD IL-2) therapy for metastatic melanoma or…
- Trial name
- HDIL2/Emend (NCT01874119)
- Testing
- Fosaprepitant
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- St. Louis University
Breast Carcinoma
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving…
- Trial name
- NCT03367572
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride
- Where
- 18 sites in United States
- Volunteers
- 1,363 people
- Sponsor
- University of Rochester NCORP Research Base
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
The goal of this clinical research study is to learn if adding dronabinol in combination with the standard of care (dexamethasone and palonosetron) can better help to control nausea and vomiting in patients receiving…
- Trial name
- NCT00553059
- Testing
- dexamethasone, dronabinol, palonosetron hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapy-Induced Nausea and Vomiting
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.
- Trial name
- NCT00818259
- Testing
- Experimental: aprepitant, Experimental: fosaprepitant, Comparator: ondansetron
- Volunteers
- 92 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone.
- Trial name
- NCT01339260
- Testing
- Netupitant and Palonosetron, Palonosetron, Dexamethasone
- Where
- 172 sites in United States, Argentina and 13 more
- Volunteers
- 1,455 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-Induced Nausea and Vomiting (CINV)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control…
- Trial name
- NCT01594749
- Testing
- Fosaprepitant dimeglumine, Dexamethasone, Ondansetron
- Volunteers
- 1,015 people
- Sponsor
- Merck Sharp & Dohme LLC
Anxiety, Chemotherapy-induced Nausea and Vomiting
Use of Aromatherapy to Reduce Symptom Burden
The purpose of this study is to evaluate the effect of inhaled aromatherapy on symptoms of nausea/vomiting and anxiety in patients who have received a stem cell transplant.
- Trial name
- NCT05251337
- Testing
- Essential oils
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Indiana University
Cancer
Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin
The objective of this study is to assess the efficacy and tolerability of metoclopramide added to standard antiemetic regimen for prophylaxis of cisplatin-induced emesis.
- Trial name
- NCT01093690
- Testing
- metoclopramide
- Where
- Thailand
- Volunteers
- 162 people
- Sponsor
- Mahidol University
Breast Cancer Stages I Through III
The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients
The goal of this study is to determine if acupuncture improves multiple symptoms associated with chemotherapy on the MD Anderson Symptom Inventory (MDASI): nausea, vomiting, fatigue, anxiety, anorexia, pain, disturbed sleep…
- Trial name
- NCT01996410
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- OhioHealth
Nausea With Vomiting Chemotherapy-Induced
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV).
- Trial name
- NCT04592198
- Testing
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Ovarian Cancer, Uterine Cancer
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Nausea and vomiting are two of the more concerning adverse outcomes associated with chemotherapy in the treatment of gynecologic malignancies.
- Trial name
- NCT01432015
- Testing
- fosaprepitant, aprepitant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gynecologic Oncology Associates